araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 56-year-old female with basal cell carcinoma; genetic feature: PTCH1

Clinical trial: Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx

Summary: RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment for laryngeal cancer.
  PURPOSE: This phase I trial is studying the side effects and best dose of laser light therapy when given together with HPPH in treating patients with dysplasia, cancer in situ, or invasive cancer of the larynx.

Detailed description: OBJECTIVES:
  Primary
  -  To determine the maximum tolerated dose of laser light therapy using a fixed dose of HPPH in patients with dysplasia, squamous cell carcinoma in situ, or T1 squamous cell carcinoma of the larynx.
  Secondary
  -  To determine response in patients treated with this regimen.
  OUTLINE: This is a dose-escalation study of laser light therapy.
  Patients undergo photodynamic therapy comprising HPPH IV over 1 hour on day 1 and laser light therapy to the tumor on day 2. Approximately 8 weeks later, patients with a partial response, no response, or a geographical miss may receive a second course of treatment.
  After completion of study treatment, patients are followed at 1 week, 1 month, 3 months, and then periodically thereafter.

Eligibility: DISEASE CHARACTERISTICS:
  -  Biopsy-confirmed diagnosis of 1 of the following:
  -  Mild to severe dysplasia of the larynx
  -  Dysplastic lesions > 3 mm in thickness
  -  Squamous cell carcinoma in situ of the larynx
  -  T1 squamous cell carcinoma of the larynx
  -  Tumor > 3 mm in thickness
  -  No T2-T4 squamous cell carcinoma of the larynx
  -  Newly diagnosed or recurrent disease
  PATIENT CHARACTERISTICS:
  -  ECOG performance status 0-2
  -  Total bilirubin > 2.0 mg/dL
  -  Creatinine > 2.0 mg/dL
  -  SGOT > 3 times upper limit of normal (ULN)
  -  Alkaline phosphatase > 3 times ULN
  -  Not pregnant or nursing
  -  Negative pregnancy test
  -  Fertile patients must use effective contraception during and for 3-6 months after completion of study treatment
  -  No porphyria
  -  No hypersensitivity to porphyrin or porphyrin-like compounds
  PRIOR CONCURRENT THERAPY:
  -  Any prior therapy allowed
  -  At least 4 weeks since prior and no concurrent chemotherapy or radiotherapy

Relevance to patient case: not relevant
Patient case: 56-year-old female with basal cell carcinoma; genetic feature: PTCH1

Clinical trial: Interest of a Systematic Biopsy for Hard-to-heal Leg Ulcers

Summary: Primary aim of the study : to evaluate the prevalence of ulcerated cutaneous carcinoma or malignant degeneration, in leg ulcers, presumed of vascular origin and without evidence of healing despite 3 months of adequate treatmentSecondary aims of the study : to evaluate the interest of immunostainings for desmogleins 1-2 and p16 on biopsies to differentiate between pseudo epitheliomatous hyperplasia and squamous cell carcinoma ; and the prognosis of diagnosed carcinomas at 12 monthsStudy hypothesis : systematic biopsies of hard-to-heal leg ulcer may help to detect ulcerated carcinomas misdiagnosed as vascular ulcer or malignant degeneration of leg ulcer.

Detailed description: Prospective multicentric inclusion of 150 patients with leg ulcers without any evidence of healing (no change or increase of ulcer area) despite 3 months of adequate treatment The study population consisted of consecutive patients with one or more leg ulcers, diagnosed as related to venous insufficiency, associated or not with concomitant arterial insufficiency. All patients undergo a standard treatment including compression therapy adapted to the ankle brachial index and a local treatment depending on the wound stage.At inclusion, systematic punch biopsies (5-6 mm) are taken as part of routine clinical care under local anaesthetic by an experienced clinician: 1 to 2 biopsies in the edges and 1 to 2 biopsies in the wound bedSpecimens are transported in formalin solution to the usual pathology laboratory of the investigator. At the end of the study, specimens will be sent for immunostainings in a single pathology laboratory (Rouen, France)Treatments and/or other investigations are decided by the investigatorAt 12 months of usual follow-up, final diagnosis and prognosis are noted in the study file by the investigator.

Eligibility: Inclusion Criteria:
  -  leg ulcer of more than 3 months of duration
  -  leg ulcer presumed of vascular origin
  -  adequate etiologic treatment since 3 months
  -  absence of evidence of healing : absence of reduction of wound area or increase in wound area and/or in depth
  Exclusion Criteria:
  -  hypertensive ulcer
  -  vasculitis
  -  treatment by cytotoxic agents or steroids in the previous 3 months

Relevance to patient case: not relevant
Patient case: 56-year-old female with basal cell carcinoma; genetic feature: PTCH1

Clinical trial: Efficacy of the SurgiStim3 Electrical Stimulation Device in Persons Undergoing Anterior Cruciate Ligament Repair

Summary: The purpose of this study is to determine whether a functional electrical stimulation device, the SurgiStim3, decreases pain, pain medications and/or edema in patients undergoing anterior cruciate ligament repair.


Eligibility: Inclusion Criteria:
  -  Agree to provide informed consent to be included within this ACL study
  -  Demonstrate a continued willingness to be compliant with the parameters established under the study;
  -  Have no history of drug or alcohol abuse in the last 2 years;
  -  Be either a male or female adult between the ages of 18 and 64;
  -  Be undergoing a surgical repair of the anterior cruciate ligament (ACL) using either a hamstring, patella tendon, Achilles tendon, or allograft procedure; and
  -  Understand that there is no financial remuneration for participation in the study.
  Exclusion Criteria:
  -  Pregnant women
  -  Insulin dependent diabetic patients
  -  Patients with a demand type pacemaker
  -  Patients who have a malignant tumor (other than basal cell epithelioma)
  -  Patients with a known history of alcohol or drug abuse in the last 2 years
  -  Patients who will not agree to provide informed consent to be included within this ACL study
  -  Patients who demonstrate a continued unwillingness to be compliant with the parameters established under this study.
  -  "Poor healers" as identified by the patient's medical history
  -  Patients who have a history of sensitivity to surgical tape, electrode adhesives, etc.
  -  Patients with a known history of RSD (reflex sympathetic dystrophy)
  -  Patients with a history of chronic pain (on opiates or high dosage of NSAIDS for 3 months or greater)
  -  Patients who have previously undergone an ACL reconstruction on the same knee
  -  Patients with clinically varicose veins (clinically significant or symptomatic)
  -  Patients whose history shows an abuse of diuretics or anti-inflammatory medications
  -  Patients who will undergo multiple ligament surgery (i.e., ACL plus PCL, MCL, and/or LCL)

Relevance to patient case: not relevant
Patient case: 56-year-old female with basal cell carcinoma; genetic feature: PTCH1

Clinical trial: microRNA Expression in Renal Cell Carcinoma

Summary: In this study, renal cell carcinoma (RCC) related miRNA and the target genes of related miRNA will be examined in order to investigate the role of miRNA in the formation of RCC and look for the biomarker of RCC.

Detailed description: Due to the lack of specific indicators for the early diagnosis of RCC, the RCC patients often have distant metastasis when diagnosed and their five-year survival rate is much low. Therefore, the biological markers of RCC are needed for early detection, early treatment and improvement of the survival rate of RCC patients.
  MiRNA and tumor are closely related. MiRNA can control the important cancer-related genes and participate in the tumor cell proliferation, apoptosis, invasion and angiogenesis.
  In this study, RCC related miRNA and the target genes of related miRNA will be examined,and the relationship between RCC related miRNA and the RCC pathological types, TNM (tumor-nodes-metastasis) stages and prognosis will be analyzed. The purpose of this study is to investigate the role of miRNA in the formation of RCC and look for the biomarker of RCC.

Eligibility: Inclusion Criteria:
  -  Patients with primary renal cell carcinoma.
  -  Subjects who agree to participate in the study and sign the informed consent.
  Exclusion Criteria:
  -  Patients with secondary renal cell carcinoma.
  -  Subjects who refuse to participate in the study and sign the informed consent.

Relevance to patient case: not relevant
Patient case: 56-year-old female with basal cell carcinoma; genetic feature: PTCH1

Clinical trial: Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer

Summary: RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment against skin cancer.
  PURPOSE: This phase II trial is studying the side effects of photodynamic therapy using aminolevulinic acid and to see how well it works in treating patients with skin cancer.

Detailed description: OBJECTIVES:
  -  To determine the safety and efficacy of intralesional photodynamic therapy using aminolevulinic acid and non-coherent blue light in patients with nodular basal cell carcinoma.
  OUTLINE: Patients undergo photodynamic therapy comprising intralesional injection of aminolevulinic acid followed by non-coherent blue light therapy over approximately 17 minutes. Patients may undergo re-treatment with photodynamic therapy 8 weeks later.
  Patients undergo photographic assessment of their skin lesions at baseline, 8 weeks, 16 weeks, and then at 1 and 2 years to evaluate healing time, clinical improvement, and side effects.
  Patients undergo biopsies of their skin lesions at 16 weeks and then at 1 and 2 years to confirm histological clearance.

Eligibility: DISEASE CHARACTERISTICS:
  -  Biopsy-proven basal cell carcinoma on the trunk or extremities
  -  Tumor size ≤ 2 cm in diameter
  PATIENT CHARACTERISTICS:
  -  Willing and able to comply with all follow-up requirements
  -  Mentally competent
  -  No active, localized, or systemic infections
  -  Not immunocompromised
  -  No coagulation disorder
  -  No photosensitivity or allergy to sunlight
  -  Not pregnant or nursing
  -  No history of keloid formation
  -  No history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins, or photodermatosis
  PRIOR CONCURRENT THERAPY:
  -  No prior gold therapy
  -  No prior radiotherapy to the trunk and extremities
  -  More than 24 months since prior oral retinoids (e.g., isotretinoin or acitretin) or photosensitizing drugs (e.g., Declomycin®)
  -  More than 1 year since prior collagen or other injections, Botox® injections, chemical peels, dermabrasion, or resurfacing procedures
  -  More than 1 month since prior topical retinoid therapy
  -  No concurrent aspirin or antioxidants
  -  No concurrent anticoagulation medications

Relevance to patient case: not relevant
Patient case: 56-year-old female with basal cell carcinoma; genetic feature: PTCH1

Clinical trial: Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer

Summary: The purpose of this study is to determine the difference of skin carotenoid levels between subjects with previous squamous cell carcinomas (SCC), subjects with previous basal cell carcinomas (BCC) and a control group.

Detailed description: There has been experimental and clinical research evaluating association of different carotenoids and incidence of malignancies, including Non- Melanoma Skin Cancer (NMSC). An easy and inexpensive way to determine which subjects would benefit from supplementation with carotenoids or retinoids could be the measurement of skin carotenoid levels.The least invasive way to perform it is through Raman spectroscopy which is a technique that uses a laser light that can be used to quantify carotenoids on the skin. We will compare the skin carotenoid levels of subjects with previous history of SCC or BCC and subjects without history of previous NMSC.

Eligibility: Inclusion Criteria:
  -  Subjects between 50 and 75 years old without history of previous SCC or BCC.
  -  Fitzpatrick skin types I-IV.
  -  Willing and able to understand and sign informed consent.
  -  Able to complete study and comply with study procedures
  Exclusion Criteria:
  -  Regular ingestion of supplements containing carotenoids or vitamin A in the past 4 weeks.
  -  Use of topical retinoids in the past 4 weeks.
  -  Treatment with systemic retinoids in the past 6 months.
  -  Dermatologic conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, palmar psoriasis, hand dermatitis or palmo-plantar keratoderma.
  -  Previous history of psoriasis.
  -  Clinically significant abnormal findings or conditions, which might, in the opinion of the Principal Investigator, interfere with study evaluations or pose a risk to subject safety during the study.
  -  Subjects who are known to be pregnant or planning a pregnancy.

Relevance to patient case: not relevant
Patient case: 56-year-old female with basal cell carcinoma; genetic feature: PTCH1

Clinical trial: Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin

Summary: The purpose of this study is to estimate and define the mean number, degree of confluence, and depth of penetration of melanocytes in chronically sun exposed skin of the head and neck using Mart-1 immunostains on frozen sections. The study was conducted to confirm whether similar results were found using permanent sections. The present study used hematoxaline and eosin (H&E) staining as well as Mart-1 staining, and included patients from both Mayo Clinic Jacksonville and Rochester.

Detailed description: For each study participant we recorded their age, sex, state they lived in, tumor type, tumor location, recent sun exposure (during the two weeks prior to the surgery), whether or not a follicle was present on the slide, and if so the follicular extension (mm) from the granular layer, presence of atypia, nesting, pagetoid spread. Two slides were obtained; one stained with Mart-1; the other with H&E. For both, melanocyte counts per high power field (400 X HPF magnification) were obtained in three locations of the slide. The mean of the 3 counts was used for analysis, though the individual counts were considered in some data summaries (see below). Classification of photo-aging according to the Glogau scale was noted by the surgeon as type1: "no wrinkles"; type II "wrinkles in motion"; type III "wrinkles at rest" and type IV "only wrinkles." Confluence was categorized by the number of adjacent melanocytes as none, mild (2 side-by-side), moderate (3-6), or severe (7 or more).

Eligibility: Inclusion Criteria:
  -  Participants undergoing Mohs and reconstructive surgery for basal cell and squamous cell carcinoma of the face and neck
  Exclusion Criteria:
  -  Participants with a history of radiation to the head and neck were excluded.

Relevance to patient case: not relevant
Patient case: 56-year-old female with basal cell carcinoma; genetic feature: PTCH1

Clinical trial: Basal Cell Carcinoma Recurrence After Mohs Surgery

Summary: Basal cell carcinoma (BCC) is the most common skin cancer in the US and can cause significant adverse effects.
  Mohs micrographic surgery, the treatment of choice for higher risk BCC, allows for removal of lesions with preservation of healthy tissue. Although the BCC recurrence rate post Mohs surgery is estimated at 1-2%, recent data is lacking to validate this historical measurement.
  Our purpose is to determine the current recurrence rate of BCC after Mohs surgery.

Detailed description: Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer in the United States, affecting nearly one million of all Americans. While BCC is rarely mortal, it has significant associated physical, psychological, and monetary costs to patients such as disfigurement and sensory loss. Individuals who have been diagnosed with at least one BCC lesion are likely to be diagnosed with more in the future. Treatment of these lesions and recurrent physician appointments can be a great inconvenience to patients, resulting in expenses to patients and loss of work and family time.
  The Mohs surgery technique is associated with a low recurrence rate for BCC and is preferred for higher risk tumors and for tumors in cosmetically sensitive sites on the head and neck. While recurrence rates of BCC post Mohs are 1-2% for primary basal cells, recent data is not available to validate this historical assessment. Currently, comprehensive rates of recurrence are not available because a national registry of recurrence rates for BCC and squamous cell carcinoma (SCC) does not exist.
  The purpose of this study is to both historically and prospectively assess current basal cell carcinoma recurrence rates in patients undergoing Mohs micrographic surgery.

Eligibility: Inclusion Criteria:
  -  Subjects with BCC lesions on the head, neck, genitalia, hands, or feet
  -  Subjects who have undergone Mohs micrographic surgery for BCC on or before December 31, 2006
  -  Subjects with a medical record at the respective site
  -  Subjects in a stable health condition, as determined by the principle investigator
  Exclusion Criteria:
  -  Subjects with basal cell nevus syndrome
  -  Subjects with lesions only in areas other than the head, neck, genitalia,
  -  hands and feet
  -  Subjects who have not followed up through the Department of Dermatology
  -  Subjects with recurrent BCC lesions diagnosed on or prior to the recorded date of Mohs surgery

Relevance to patient case: not relevant
Patient case: 56-year-old female with basal cell carcinoma; genetic feature: PTCH1

Clinical trial: Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer

Summary: The purpose of this study is to determine whether it is safe to treat lung cancer patients who have undergone an attempt at curative resection with the combination of docetaxel and carboplatin.

Detailed description: Patients with stage Ib - IIIa NSCLC participated in an open-label, single arm study to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent. The primary endpoint of the study was safety, as reflected by a febrile neutropenia rate of <10%. Other endpoints assessed protocol compliance and the impact of minimally invasive surgical technique.

Eligibility: Inclusion Criteria:
  -  Non-small cell lung cancer stage IB - IIIA, complete resection with mediastinal lymph node dissection
  -  ECOG status 0-1
  -  >14 and <56 days since resection
  Exclusion Criteria:
  -  Prior chemotherapy and/or radiation therapy for lung cancer
  -  Peripheral neuropathy > grade 1
  -  Concurrent other malignancies, other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
  -  Medical condition that will not permit treatment or follow up according to the protocol
  -  Prior treatment with docetaxel or carboplatin
  -  Hypersensitivity to polysorbate 80, platinum-containing compounds or mannitol
  -  Treatment with other investigational anti-cancer drugs within 30 days of registration
  -  Pregnant or nursing women
  -  HIV-positive patients

Relevance to patient case: not relevant
Patient case: 56-year-old female with basal cell carcinoma; genetic feature: PTCH1

Clinical trial: Immunoreactivity to Cetuximab in Cancer Patients

Summary: RATIONALE: Studying samples of blood in the laboratory may help doctors predict which patients will develop hypersensitivity to cetuximab.
  PURPOSE: This research study is looking at hypersensitivity to cetuximab in patients with head and neck cancer or advanced colorectal cancer previously treated with cetuximab.

Detailed description: OBJECTIVES:
  -  To examine serum samples from patients with head and neck cancer or advanced colorectal cancer previously treated with cetuximab for the presence of antibodies against cetuximab.
  OUTLINE: Serum samples are examined by immunoreactivity screening of IgE, IgG, IgA, and IgM antibodies and complement reaction.

Eligibility: DISEASE CHARACTERISTICS:
  -  Diagnosis of one of the following:
  -  Head and neck cancer
  -  Advanced colorectal cancer
  -  Previously treated with cetuximab
  -  Serum samples available from patients enrolled in one of the following clinical trials:
  -  VU-VICC-GI-0410 (colorectal cancer)
  -  VU-VICC-GI-0622 (colorectal cancer)
  -  VU-VICC-HN-0356 (head and neck cancer)
  PATIENT CHARACTERISTICS:
  -  Not specified
  PRIOR CONCURRENT THERAPY:
  -  See Disease Characteristics

Relevance to patient case: not relevant
Patient case: 56-year-old female with basal cell carcinoma; genetic feature: PTCH1

Clinical trial: Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

Summary: RATIONALE: Measuring levels of transforming growth factor-beta (TGF-beta) in the blood of patients with epithelial cancers (head and neck, lung, breast, colorectal, and prostate) may help doctors predict how patients will respond to treatment with radiation therapy.
  PURPOSE: This research study is measuring levels of TGF-beta in patients with epithelial cancers who are undergoing radiation therapy.

Detailed description: OBJECTIVES:
  -  To determine whether there is a dose-dependent increase in TGF-beta following radiotherapy in patients with epithelial cancers.
  OUTLINE: Patients undergo blood sample collection prior to treatment, 24-72 hours after the first fraction of radiotherapy, and at the end of radiotherapy. Patients will also be asked for a weekly blood sample, but this is optional. Samples are analyzed to compare pre- and post-treatment TGF-beta levels.

Eligibility: DISEASE CHARACTERISTICS:
  -  Known diagnosis of an epithelial cancer, including any of the following:
  -  Head and neck
  -  Lung
  -  Breast
  -  Colorectal
  -  Prostate
  -  Radiotherapy must be a component of planned treatment therapy
  PATIENT CHARACTERISTICS:
  -  No serious medical or psychiatric illnesses which would prevent informed consent

Relevance to patient case: not relevant